

Australian Government

Department of Health and Aged Care

Life Saving Drugs Program (LSDP) Reapplication form for subsidised treatment for Mucopolysaccharidosis Type II (MPS II)

Patient ID: MPS II

Dosing details

Generic name of medicine requ	actad	
Generic name of medicine requi	esteu.	
Patient's weight		
kg		
Dosage of medicine requested:		
mg		vials
Is this a dose change for the pa	tient? Yes N	lo 🗌
Eligibility confirmation of	checklist	
The treating physician must in the patient meets the eligibility requirements for ongoing LSD	r criteria and data	
 I have assessed the patient s application/previous reapplica last 12 months. 		
2. The patient continues to mee requirements listed in the <u>Guide</u> treatment of MPS II through the <u>Program</u> (the Guidelines).	elines for the	
3. The patient has demonstrat improvement or stabilisation o		
4. The patient has not develop conditions listed in the exclusic Guidelines.	-	
Data requirement check	dist	
5. I have submitted a clinic lette patient's recent medical and sur general description of their hea	rgical history and	
6. I have provided copies of all the completed Excel spreadshee	-	

7. I confirm the test results and clinic letter provided are not more than 12 months old and have not been used to support a previous application or reapplication.

Treating physician's declaration

I confirm that:

I am the treating physician of the patient as stated in this form and have relevant specialist registration. I hereby reapply for Australian Government subsidised access to treatment for MPS II through the LSDP on behalf of my patient.

I declare that:

- The information provided in this form and supporting documents is complete and correct.
- To the best of my knowledge and belief, my patient continues to be eligible to receive subsidised treatment for MPS II through the LSDP, in accordance with the Guidelines.
- I am aware that the patient must be an Australian citizen or permanent Australian resident who continues to qualify for Medicare.

I understand that:

- I have an ongoing obligation to ensure that my patient continues to meet the eligibility criteria to receive subsidised treatment through the LSDP.
- Making a false or misleading declaration is a serious offence and may lead to further investigations.
- I must submit a separate reapplication for subsidised treatment through the LSDP by 1 May each year if I wish for my patient to continue to receive subsidised treatment.

I agree that:

If I become aware that my patient no longer meets the eligibility criteria for subsidised access to treatment through the LSDP at any time, I will notify the LSDP immediately.

Treating physician's full name

Treating physician's signature

Date

Privacy notice

The Australian Government Department of Health and Aged Care (the Department) is collecting this patient's personal information, including sensitive health information, for the purpose of re-assessing this patient's eligibility to receive subsidised treatment for MPS II through the LSDP. If subsidised treatment through the LSDP is approved, the Department will continue to collect personal information about this patient in order to process a confirmation of ongoing eligibility.

If all of the personal information required is not provided, the Department will not be able to process the reapplication to confirm eligibility to receive subsidised treatment through the LSDP.

The Department will disclose personal information to this patient's treating physician, pharmacists, clinic nurses and other health care professionals who may be involved in the administration of this patient's treatment.

The Department will disclose this patient's personal information including Medicare number to Services Australia in order to confirm Medicare eligibility and permanent Australian residency requirements.

'De-identified' personal information will be used for the purpose of the evaluation of the LSDP, which may include the provision of these data to third parties contracted by the Department for this purpose.

The Department has an Australian Privacy Principles (APP) privacy policy which can be read at www.health.gov.au/resources/publications/privacy-policy

The Department can be contacted by telephone on (02) 6289 1555 or freecall 1800 020 103 or by using the online enquiries form at www.health.gov.au

A copy of the APP privacy policy can be obtained by contacting the Department using the contact details set out above. The APP privacy policy contains information about:

- how to access personal information the Department holds and how to seek correction of it; and
- how to complain about a breach of the APP or the Australian Government Agencies Privacy Code and how the Department will deal with complaints.

The Department is unlikely to disclose personal information to overseas recipients.

Patient's details

Medicare care number				
Ref no.				
Mr Mrs Miss Ms Other				
Given name				
Family name				
Residential address				
Suburb State Post Code				
Date of birth				

Consent to collection of sensitive information for treatment and after cessation of treatment

I consent to the Department collecting genetic and health information about the patient identified on this application form for the purpose indicated above.

I consent to the Department requesting and obtaining sensitive information and supplemental information from the treating physician regarding the reason(s) for ceasing treatment including cause of death, if applicable.

If this information is not able to be obtained from the treating physician, I consent to the Department requesting and obtaining this information from other Government agencies and non-government organisations.

The information collected in this process is for the purpose of determining the cause of discontinuation of subsidised treatment.

Continuing eligibility for subsidised treatment for MPS II through the LSDP

I understand that:

- if I/the patient fail to comply with the associated monitoring and assessment requirements, without an acceptable reason to do so, I/the patient will no longer be eligible to receive subsidised treatment through the LSDP.
- if treatment does not result in a clinically meaningful effect, subsidised treatment through the LSDP may be discontinued.

Fick only one as appropriat	e:
-----------------------------	----

Patient Parent Responsible Person*

Full name (print in BLOCK LETTERS)

Date			

*A Responsible Person is an individual authorised to act on behalf of the patient and can include (please tick only one as appropriate):

- A guardian of the patient who is a child
- An enduring guardian
- A person with an enduring power of attorney in relation to the patient, recognised under a relevant state or territory law
- A person who has been nominated in writing by the patient while the patient was capable of giving consent
- A person authorised to act on the patient's behalf as recognised by other relevant laws

If it is not possible or if it is impracticable to obtain written consent, a member of the patient's clinical care team may obtain verbal consent from the patient or where relevant, the patient's parent or other Responsible Person.

Please read the below Privacy Notice and consent wording to the patient or their parent or Responsible Person; and complete the rest of the form below.

To be read to the patient or their parent or Responsible Person	To be completed by the appropriate clinical care team member once verbal consent has been obtained:	
Privacy Notice	once verbar consent has been obtained:	
The Australian Government Department of Health and Aged Care (the Department) needs to collect [your/the patient's] personal information, including sensitive health information, from [your/their] treating physician for the purpose of re-assessing [your/the patient's] eligibility to receive subsidised treatment through the LSDP.	Please tick the boxes and complete Parts A to B below. I have read the above Privacy Notice to the patient or their parent or Responsible Person, or have otherwise explained how the patient's personal information will be collected, used and disclosed for the purposes of the patient's reapplication for continuing treatment through the LSDB	
[Your/the patient's] personal information being collected by the Department for the purpose of re-assessment includes [your/the patient's]: - Name - Address - Medicare number - Date of birth - Genetic and health information	treatment through the LSDP. The patient or their parent or Responsible Person has provided their verbal consent for the patient's personal information to be collected, used and disclosed in the manner described in the Privacy Notice above. The patient or their parent or Responsible Person understands the requirements for maintaining eligibility for subsidised treatment through the LSDP.	
- Sensitive information and supplemental information regarding the reason or reasons for ceasing treatment including cause of death		
The Department will disclose [your/the patient's] personal information to [your/their] treating physician, pharmacists, clinic nurses and other		
health care professionals who may be involved in the administration of [your/the patient's] treatment.	Part A: Details of person who provided consent	
The Department will disclose [your/the patient's] personal	Please indicate who provided the consent:	
information including Medicare number to Services Australia to confirm Medicare eligibility and permanent Australian residency requirements.	Patient Parent Responsible Person* * *A Responsible Person is an individual authorised to act on behalf of the patient and can include (please tick only one as appropriate):	
The Department will use 'de-identified' information for the purpose of evaluating the LSDP, which may include the provision of de-identified information to third parties contracted by the Department for this purpose.	 A guardian of the patient who is a child An enduring guardian A person with an enduring power of attorney in relation to the patient, recognised under a relevant state or territory law 	
The Department is unlikely to disclose [your/the patient's] personal information to overseas recipients.	- A person who has been nominated in writing by the patient while the patient was capable of giving consent	
If you do not provide the personal information required, the Department will not be able to process [your/the patient's]	- A person authorised to act on the patient's behalf as recognised by other relevant laws	
reapplication to receive subsidised treatment through the LSDP.	Name of person providing consent (print in BLOCK LETTERS)	
<i>Do you consent to the Department's collection of [your/the patient's]</i> <i>health information from your treating physician?</i>		
	Part B: Details of person who obtained the consent:	
If the above information cannot be obtained from your treating physician, do you consent to the Department obtaining this information from other government agencies and non-government organisations?	Name of person who obtained consent (print in BLOCK LETTERS)	
Ongoing eligibility for subsidised treatment for MPS II through the LSDP	Signature of person who obtained consent	
Access to treatment through the LSDP is provided in accordance with the <i>Guidelines for the treatment of MPS II through the Life Saving Drugs</i> <i>Program.</i> A copy of this Guideline can be found on the Department's website.	Date	
Do you understand that subsidised treatment through the LSDP may be discontinued if: - [you/the patient] fail/s to comply adequately with treatment; or - [you/the patient] fail/s to provide test results evidencing the		

Page 3 of 3

effectiveness of the therapy; or

- the treatment does not result in a clinically meaningful effect?